rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

AMETEK, Inc.

AME · NYSE

Health CareLife-science toolsIn trendDefense-Tech

AME stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 5.0% above that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
52 in a row
Industry in uptrend
54% +4 in 4 wk
Insider buys, 12 months
$2.0M
Insider sales, 12 months
$36.6M
Officials’ trades on record
31

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.

20 Apr – 19 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$32.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

31 disclosed lines: House 19, Senate 8, executive 4; 17 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k23 Jun 2026filed 22 Aug 2026
Alan Armstrong Senate: U.S. Senate eFDSenatorbought$1k–$15k27 Mar 2026filed 21 Jul 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k10 Feb 2026filed 9 Mar 2026
Arjun Mody Executive branch: Office of Government EthicsSocial Security Administrationsold$1k–$15k30 Jan 2026filed 10 Apr 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k9 Jan 2026filed 13 Feb 2026
Dan Newhouse House: U.S. House ClerkWA04boughtspouse$1k–$15k18 Aug 2025filed 17 Sep 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08sold$1k–$15k8 Apr 2025filed 8 May 2025
Val T. Hoyle House: U.S. House ClerkOR04soldspouse$1k–$15k24 Jan 2025filed 12 Sep 2025
Val T. Hoyle House: U.S. House ClerkOR04boughtspouse$1k–$15k29 Oct 2024filed 12 Sep 2025
Tommy Tuberville Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k19 Jan 2024filed 14 Feb 2024
Dan Sullivan Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k22 Aug 2023filed 22 Sep 2023
Dan Sullivan Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k22 Aug 2023filed 18 Sep 2023

Insiders

Buy orders, 12 months1
Sale orders, 12 months8
Buyers · sellers1 · 7
WhoDidSharesTraded
Nick L. StanageDirectorbought4,000at $255.8511 Aug 2026filed 12 Aug 2026
David F. HermancePRESIDENT - ELECTROMECHANICALsold6,608at $254.007 Aug 2026filed 10 Aug 2026
Thomas A. AmatoDirectorsold530at $216.7824 Mar 2026filed 25 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Nick L. Stanage Company insiderDirector · last 11 Aug 20261 · 0
David F. Hermance Company insiderPRESIDENT - ELECTROMECHANICAL · last 7 Aug 20260 · 3
Donald J. Trump Executive branchWhite House Office · last 23 Jun 20261 · 0
Ronald J. Oscher Company insiderCHIEF ADMINISTRATIVE OFFICER · last 27 May 20260 · 13
Alan Armstrong SenateSenator · last 27 Mar 20261 · 0
Thomas A. Amato Company insiderDirector · last 24 Mar 20261 · 8
Dalip Puri Company insiderExecutive VP- CFO · last 22 Mar 20260 · 0
David A. Zapico Company insiderCHIEF EXECUTIVE OFFICER · last 22 Mar 20260 · 25
Emanuela Speranza Company insiderCHIEF COMMERCIAL OFFICER · last 22 Mar 20260 · 4
John Wesley Hardin Company insiderPRES. - ELECTRONIC INSTRUMENTS · last 22 Mar 20260 · 30
Robert Amodei Company insiderSenior VP, Controller · last 22 Mar 20260 · 0
Thomas C. Marecic Company insiderPRES. - ELECTRONIC INSTRUMENTS · last 22 Mar 20260 · 18

Same industry

OABI OmniAbLeading+67%
TXG 10x GenomicsLeading+59%
AVTR AvantorLeading+45%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+35%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202536.0%
Operating profit marginFY 2025 · to 31 Dec 202525.8%
Free cash flow marginFY 2025 · to 31 Dec 202522.6%
Return on capital employedFY 2025 · to 31 Dec 202514.4%
Cash conversionFY 2025 · to 31 Dec 2025122%
Debt to equityFY 2025 · to 31 Dec 20250.33×
Research spendFY 2025 · to 31 Dec 20253.2%
Dividend growthFY 2025 · to 7 Feb 202510.7%
Share count trendFY 2025 · to 30 Jan 2026-0.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$458.0M
Free cash flowFY 2025 · to 31 Dec 2025$1.7B

Analyst forecasts

No analyst forecasts yet.